TWP-101

DRUG2 trials

Sponsors

Shandong TheraWisdom Biopharma Co., Ltd.

Conditions

Advanced MelanomaAdvanced Solid TumorAdvanced Urothelial Carcinoma

Phase 1

Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

Shandong TheraWisdom Biopharma Co., Ltd.Advanced Melanoma, Advanced Urothelial Carcinoma

Start: 2021-02-07End: 2022-12-31Target: 76Updated: 2021-07-23

The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor

Shandong TheraWisdom Biopharma Co., Ltd.Advanced Solid Tumor

Start: 2021-08-30End: 2023-12-31Target: 58Updated: 2021-07-27

Related Papers

Early safety and efficacy from a phase I clinical study of TWP-101, a novel CD137 agonist antibody, in patients with advanced melanoma and urothelial carcinoma.

Journal of Clinical Oncology2023-06-01